Economic impact of treatment options for hepatic encephalopathy

Seminars in Liver Disease

Volumn 27, Issue SUPPL. 2, 2007, Pages 26-31

  Leevy, Carroll B ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Health care utilization; Hepatic encephalopathy; Lactulose; Rifaximin

Indexed keywords

LACTITOL; LACTULOSE; METRONIDAZOLE; NEOMYCIN; RIFAXIMIN;

CHRONIC LIVER DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HEPATIC ENCEPHALOPATHY; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; LONG TERM CARE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED STATES;

EID: 34548151251     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984572     Document Type: Review

References (19)

1. American Gastroenterological Association. The Burden of Gastrointestinal Diseases. Chapter 5: Hepatobiliary and pancreatic disorders. Available at: www.gastro.org/user-assets/Documents/burden-report.pdf. Accessed January 5, 2007
2. Mas A. Hepatic encephalopathy: from pathophysiology to treatment. Digestion 2006;73(suppl 1):86-93
3. Abou-Assi S, Vlahcevic ZR. Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible. Postgrad Med 2001;109:52-60, 63
4. Amodio P, Del Piccolo F, Petteno E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 2001;35:37-45
5. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96:2718-2723
6. Ytting H, Moller S, Henriksen JH, et al. Prognosis in patients with cirrhosis and mild portal hypertension. Scand J Gastroenterol 2006;41:1446-1453
7. Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000;95:2029-2034
8. Kircheis G, Wettstein M, Timmermann L, et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002;35:357-366
9. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998;28:45-49
10. Das A, Dhiman RK, Saraswat VA, et al. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001;16:531-535
11. Han MK, Hyzy R. Advances in critical care management of hepatic failure and insufficiency. Crit Care Med 2006;34: S225-S231
12. Agency for Healthcare Research Quality. HCUPnet: Healthcare Cost and Utilization Project. Available at: http://hcupnet.ahrq.gov/HCUPnet.jsp?Id= DBE1CCF502E0C25DForm=SelQUERYTYPEJS=YAction=%3 E3ENext3E3E_QUERYTYPE=Trends. Accessed February 2007
13. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006;101:2128-2138
14. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-1569
15. Koo HL, DuPont HL. Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther 2006;4:417-427
16. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(suppl 1):13-27
17. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006;38:3552-3555
18. Spiegel B, Huang E, Esrailian E. Is rifaximin cost-effective in the management of hepatic encephalopathy? Gastroenterology 2006;130:A-806
19. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007;52:737-741